Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
05:34am, Tuesday, 21'st Jan 2025
2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 (^GSPC 1.00%) and 28.6% for
Merck: 3x Pipeline And Undervaluation Make It A Buy
08:30am, Monday, 20'th Jan 2025
Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance wit
High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent
05:06am, Monday, 20'th Jan 2025
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Merck's robust Phase 3 pipeline, strong financials, and sustainable div
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
01:41pm, Sunday, 19'th Jan 2025
Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028. Mer
Exclusive: Kennedy played key role in vaccine case against Merck
07:06am, Saturday, 18'th Jan 2025
Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los Angeles court next week
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:02am, Friday, 17'th Jan 2025
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
What's In Store For Merck Stock In 2025?
09:58am, Friday, 17'th Jan 2025
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly st
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
04:21pm, Thursday, 16'th Jan 2025
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
06:45am, Thursday, 16'th Jan 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4.
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
03:55am, Thursday, 16'th Jan 2025
If you're looking at dividend stocks as a source of income, obviously quality matters. But timing can play a role in how much income these investments generate for you, too.
Merck CEO Robert Davis goes one-on-one with Jim Cramer
08:13pm, Tuesday, 14'th Jan 2025
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.
We've seen patients on transplant lists taken off of them after starting Winrevair, says Merck CEO
08:08pm, Tuesday, 14'th Jan 2025
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.
The Big 3: PEP, AVAV, MRK
11:56am, Tuesday, 14'th Jan 2025
Kenny Polcari turns to companies which experienced recent downtrends that he believes can see bullish breakouts. He notes PepsiCo (PEP) as a major dividend grower, AeroVironment (AVAV) as a beneficiar
Merck & Co. Inc. (MRK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
10:37am, Tuesday, 14'th Jan 2025
Merck & Co. Inc. (NYSE:MRK ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 7:30 PM ET Company Participants Robert Davis - Chairman and CEO Dean Li - Executive VP & President of Merck
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
